In this episode, Sonal Kumar, MD, MPH, discusses key findings from primary biliary cholangitis (PBC) studies presented at AASLD 2024, including:

• ELATIVE, a phase III trial of elafibranor for PBC
• RESPONSE, a phase III trial of seladelpar for PBC
• ASSURE, another phase III trial of seladelpar for PBC

Presenter:
Sonal Kumar, MD, MPH
Director, Clinical Gastroenterology and Hepatology
Assistant Professor of Medicine
Weill Cornell Medical College
New York, New York

Link to full program:
https://bit.ly/41tvSDu

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Clinical gaps in the treatment of pruritus in primary biliary cholangitis (PBC) remain. In this episode, taken from a recent symposium, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with PBC, discuss emerging therapies currently in clinical trials for the management of this disease that can dramatically affect patients’ quality of life.

Listen as they discuss:

• Gaps in current management
• Patient perspectives: why we should not dismiss itching as an underlying psychologic problem
• PPAR agonists and how they affect pruritus
• BEZURSO and FITCH 
• ELATIVE
• ENHANCE and RESPONSE
• IBATs (inhibitors of bile acid transport)
• GLIMMER
• Common questions

Presenters:

Marlyn J. Mayo, MD
Professor of Internal Medicine
Division of Digestive & Liver Diseases
UT Southwestern Medical Center
Dallas, Texas

Stuart C. Gordon, MD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan

Pam Rivard, RN
Person living with PBC

Link to full program: 
https://bit.ly/3Dnfb2E

Although there is currently no FDA-approved treatment for pruritus in primary biliary cholangitis (PBC), symptoms can be mitigated with nonpharmacologic or pharmacologic agents. In this episode, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with PBC, discuss the clinical management of pruritus in PBC, including:

• Pruritus assessment tools
• Optimal use of tools, including frequency of assessment
• Current management of pruritus
• Nonpharmacologic interventions
• Pharmacologic agents
• Strategies to optimize assessment and management of pruritus
• Collaborative care
• Development of a treatment plan
• Ongoing assessment and adjustment of therapy
• Resources and support for patients

Presenters:

Marlyn J. Mayo, MD
Professor of Internal Medicine
Division of Digestive & Liver Diseases
UT Southwestern Medical Center
Dallas, Texas

Stuart C. Gordon, MD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan

Pam Rivard, RN
Person living with PBC

Link to full program: 
https://bit.ly/3Dnfb2E

In this episode, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with primary biliary cholangitis (PBC), discuss the burden of pruritus in PBC and the impact it has on quality of life, including both physical and mental health, from a patient’s perspective.

Presenters:

Marlyn J. Mayo, MD
Professor of Internal Medicine
Division of Digestive & Liver Diseases
UT Southwestern Medical Center
Dallas, Texas

Stuart C. Gordon, MD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan

Pam Rivard, RN
Person living with PBC
 

Link to full program: 
https://bit.ly/4gDGDaB

In this episode, Christopher L. Bowlus, MD, discusses recent advances in the management of primary biliary cholangitis (PBC), including:

• Treatment goals
• Use of PPAR agonists for the treatment of PBC
• Clinical trial results for elafibranor (ELATIVE), seladelpar (RESPONSE), and bezafibrate (BEZURSO)

Presenter:

Christopher L. Bowlus, MD
Lena Valente Professor and Chief
Division of Gastroenterology and Hepatology
University of California Davis School of Medicine
Sacramento, California

Link to full program:
 https://bit.ly/41tvSDu

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Listen as Elizabeth Kircher, DNP, and R. Hal Scofield, MD, discuss best practice approaches for the treatment of Sjögren’s syndrome and what’s on the horizon for future therapeutic options.

Topics include:

• Challenges in Sjogren’s Syndrome Diagnosis and Patient Understanding: Difficulties in explaining Sjogren’s syndrome diagnosis to patients unfamiliar with it and challenges in addressing the disease’s varied symptoms
• Patient Education and Communication: Strategies to prevent overwhelming patients during early visits and effective ways to address misconceptions
• Diagnostic Challenges and Misunderstandings: Differences between clinical and research criteria for diagnosis and the importance of understanding each
• Use of Ultrasound and Biopsy in Diagnosis: Benefits and limitations of ultrasound and biopsies in diagnosing Sjogren’s syndrome
• Multidisciplinary Care Barriers: Challenges in coordinating care among specialists such as ophthalmologists, dentists, and rheumatologists
• Symptomatic vs Disease-Modifying Treatments: Strategies for managing symptoms vs addressing the underlying disease with medications
• Long-term Medication and Risks: Considerations when prescribing long-term medications and immunosuppressive therapies
• Research and Emerging Therapies: Developments in Sjogren’s syndrome research, including promising medications in clinical trials
• Guideline Development and Patient Reassurance: The role of professional guidelines in shaping care and providing patients with reassurance
• Polypharmacy and Medication Reconciliation: The importance of pharmacist involvement in managing complex medication regimens for older patients

Faculty:

Elizabeth Kircher, DNP

R. Hal Scofield, MD
Member/Professor, Arthritis & Clinical Immunology
Oklahoma Medical Research Foundation
Professor, Department of Medicine, College of Medicine
University of Oklahoma Health Sciences Center
Associate Chief of Staff for Research
Oklahoma City US Department of Veterans Affairs Medical Center
Oklahoma City, Oklahoma

Link to full program:
https://bit.ly/3YKpsOE

In this CCO Nephrology podcast episode, hear from nephrologists Pietro Canetta, MD, MS, and Andy Bomback, MD, PhD, experts in clinical management and research on glomerular diseases as they discuss key updates in managing IgAN. Faculty highlight the importance of a comprehensive supportive care regimen to protect patients’ kidneys and prevent progression of disease. In addition, they review the merits and place in therapy of novel and emerging therapies. 

 Topics include:

• Supportive care as the foundation of IgAN management
• Place in therapy for new and emerging agents
  • Targeted-release formulation of budesonide
  • Endothelin receptor antagonists (eg, sparsentan)
  • Factor B inhibitors (eg, iptacopan)
• The role of clinical trial involvement

Learn more about IgA nephropathy with educational activities and resources here:  

• CME-certified text module with animated pathophysiology video and patient voice audio clip
• ClinicalThought commentaries
• Resources on IgAN from the American Kidney Fund

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD.   

 Episode outline:   

• Colchicine: inhibition of NLRP3 inflammasome assembly/activation
• Canakinumab (anti–IL-1β monoclonal antibody)
• Ziltivekimab (anti–IL-6 monoclonal antibody)
• Other emerging targets/therapies 

To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:   

• CME-certified text module with animated pathophysiology video and faculty voice audio clips 
• ClinicalThought commentaries 
• Podcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD 
• Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD 

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore new and emerging strategies to target residual risk associated with systemic inflammation in patients with ASCVD and CKD.   

 Episode outline:   

• The relationship among systemic inflammation, ASCVD, and CKD 
• The role of cardiologists and nephrologists in screening and mitigating systemic inflammation 

To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:   

• CME-certified text module with animated pathophysiology video and faculty voice audio clips 
• ClinicalThought commentaries 
• Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD 
• Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD 

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore the pathophysiology and novel therapeutic strategies to target residual inflammatory risk associated with ASCVD and CKD.   

 Episode outline:   

• Moving beyond lipid lowering to address residual inflammatory risk
• Novel anti-inflammatory targets for ASCVD 

To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:   

• CME-certified text module with animated pathophysiology video and faculty voice audio clips
• ClinicalThought commentaries
• Podcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD 
• Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD